文献速递母胎医学产科

标签标记捕获测序联合改良贝叶斯模型无创产前检测重型地贫的前瞻性临床研究

[Prospective clinical study on non-invasive prenatal testing for severe thalassemia using tag-labeled targeted capture sequencing combined with a modified Bayesian model].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2026-01-01

本研究为前瞻性队列研究,纳入452对东南亚缺失型α-地贫携带者夫妇,于妊娠11~34周采集孕妇外周血,采用标签标记靶向捕获测序检测cffDNA并用改良贝叶斯模型推断胎儿基因型,以侵入性产前诊断为金标准。442例纳入效能评价,敏感度97.89%、特异度98.56%、阳性预测值94.90%、阴性预测值99.42%,与金标准高度一致(κ=0.954,95%CI 0.920~0.988;P<0.001),符合率98.42%(435/442)。该方法不依赖父母单倍型信息,为地贫高发区双方同为SEA缺失型α-地贫携带者的夫妇提供了新的产前检测路径。

要点

  • 无创地贫检测对重型地贫敏感度97.89%、特异度98.56%。
  • 与侵入性产前诊断高度一致,κ=0.954(95%CI 0.920~0.988)。
  • 不依赖父母单倍型信息,适用于SEA缺失型α-地贫携带者夫妇。

核心结论

  • 标签标记捕获测序联合改良贝叶斯模型的无创地贫检测对重型地贫具有良好的诊断效能,不依赖父母单倍型信息。

研究设计与样本

  • 前瞻性队列研究,纳入2018年6月至2021年7月广东省妇幼保健院452对东南亚缺失型α-地贫携带者夫妇。
  • 妊娠11~34周采集孕妇外周血,以标签标记靶向捕获测序检测cffDNA,改良贝叶斯模型推断胎儿基因型。
  • 以侵入性产前诊断结果为金标准,442例纳入检测效能评价。

主要发现

  • 无创地贫检测敏感度97.89%、特异度98.56%、阳性预测值94.90%、阴性预测值99.42%。
  • 与侵入性产前诊断高度一致(κ=0.954,95%CI 0.920~0.988;P<0.001)。
  • 假阴性2例、假阳性5例,与金标准符合率98.42%(435/442)。
  • 452例中5例拒绝侵入性产前诊断、5例因样本质控未达标检测失败。

关键数值与推荐

  • 敏感度97.89%、特异度98.56%、阳性预测值94.90%、阴性预测值99.42%。
  • κ=0.954(95%CI 0.920~0.988;P<0.001)。
  • 符合率98.42%(435/442)。

临床怎么用

  • 可用于地贫高发区双方同为SEA缺失型α-地贫携带者夫妇的无创产前检测,不依赖父母单倍型信息。
  • 检测失败或样本质控未达标者需进一步处理,必要时行侵入性产前诊断。

局限性

  • 存在2例假阴性和5例假阳性,检测失败5例因样本质控未达标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the clinical performance of a non-invasive prenatal testing (NIPT) approach for fetal severe thalassemia based on tag-labeled targeted capture sequencing combined with a modified Bayesian model (referred to as noninvasive thalassemia testing). Methods: This study was a prospective cohort study involving 452 couples of the Southeast Asian deletion (SEA) type α-thalassemia carriers who were enrolled in Guangdong Women and Children Hospital from June 2018 to July 2021. Maternal peripheral blood was collected at 11-34 gestational weeks. Cell-free fetal DNA (cffDNA) in maternal plasma was analyzed by tag-labeled targeted capture sequencing, and fetal genotypes were inferred using a modified Bayesian algorithm to determine the risk of fetal severe α-thalassemia. The results of invasive prenatal diagnosis were taken as the "gold standard" to evaluate the clinical detection efficacy of this method. Results: Among the 452 pregnant women, 5 cases declined further invasive prenatal diagnosis and 5 cases failed testing due to unsatisfactory sample quality control. The remaining 442 cases were included in the testing performance evaluation. Noninvasive thalassemia testing showed a sensitivity of 97.89%, specificity of 98.56%, positive predictive value of 94.90%, and negative predictive value of 99.42%. Consistency analysis demonstrated that the prediction of severe thalassemia by noninvasive thalassemia testing was highly consistent with invasive prenatal diagnosis (κ=0.954, 95%CI: 0.920-0.988; P<0.001). The noninvasive thalassemia testing results included 2 false-negative and 5 false-positive cases, with an overall concordance rate of 98.42% (435/442) compared with the gold standard. Conclusion: The proposed noninvasive thalassemia testing method achieved good diagnostic performance for severe thalassemia without relying on parental haplotype information, providing a new prenatal testing pathway for couples in high-prevalence thalassemiat regions who are both carriers of the SEA deletion α-thalassemia. 目的: 评估基于标签标记的捕获测序和改良贝叶斯模型的胎儿重型地中海贫血(地贫)无创产前检测(简称无创地贫)的临床效能。 方法: 本研究为前瞻性队列研究,纳入2018年6月至2021年7月于广东省妇幼保健院就诊的452对东南亚(SEA)缺失型α-地贫携带者夫妇。妊娠11~34周采集孕妇外周血,通过标签标记的靶向捕获测序检测血浆中的胎儿游离DNA(cffDNA),采用改良贝叶斯模型算法推断胎儿基因型,判定胎儿罹患重型地贫的风险,最终以侵入性产前诊断结果为“金标准”,评估该方法的临床检测效能。 结果: 452例孕妇中,5例拒绝进一步行侵入性产前诊断,5例因样本质控未达标检测失败,其余442例纳入无创地贫检测效能评价。无创地贫检测的敏感度为97.89%,特异度为98.56%,阳性预测值为94.90%,阴性预测值为99.42%。一致性检验分析显示,无创地贫检测方法对于重型地贫的预测与侵入性产前诊断结果比较,高度一致(κ=0.954,95%CI为0.920~0.988;P<0.001)。无创地贫检测结果中,假阴性2例、假阳性5例,与侵入性产前诊断“金标准”的符合率为98.42%(435/442)。 结论: 本研究提出的无创地贫检测方法实现了对重型地贫的良好的诊断效能,不依赖父母单倍型信息,为地贫高发区双方同为SEA缺失型α-地贫携带者的夫妇提供了新的产前检测路径。.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Xiao X, Li QM, Wu ZL, et al. [Prospective clinical study on non-invasive prenatal testing for severe thalassemia using tag-labeled targeted capture sequencing combined with a modified Bayesian model]. Zhonghua Fu Chan Ke Za Zhi. 2026. PMID: 42045778. doi:10.3760/cma.j.cn112141-20251107-00539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。